Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to
see how well it works in treating patients with a recurrent brain tumor that has not
responded to previous surgery and radiation therapy. Imatinib mesylate may stop the growth of
tumor cells by blocking the enzymes necessary for tumor cell growth.